Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.Read More

What's Trending

Big tech must deal with scam ads under Ofcom proposals

3 Tech Stocks Poised for Comebacks

LANDBACK Action Network: A Connective Alternative to Big Tech | Nonprofit Quarterly | Civic News. Empowering Nonprofits. Advancing Justice.

Wisconsin Rapids considering law restricting where sex offenders can live

Too hot to work? What do laws in Jersey and Guernsey say?

Trump’s effort to use an obscure wartime law to deport Venezuelans has fizzled

Meta found to breach EU laws with ‘addictive’ Instagram, Facebook designs

Kentucky law requires special election to fill vacant U.S. Senate seat, not appointment

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Google Transfers Open Health Stack to Linux Foundation to Advance Global Digital Health

Wildfires across Europe have killed hundreds over the last decade

Wildfires across Europe have killed hundreds over the last decade

Half-time in Europe: keep trying

Leave A Reply Cancel Reply

What's Trending

Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

Related Posts

Leave A Reply Cancel Reply

Subscribe to MGSN